Veit Schmelmer, PhD oversees the management of Vor Bio’s clinical research programs, working with cross-functional teams and external collaborators to advance the company’s engineered Hematopoietic Stem Cell (eHSC) platform. Veit has over 25 years of experience leading the development of novel therapies for cancer, autoimmune disorders, and infectious diseases at leading biopharmaceutical companies. Most recently, Veit was a Vice President at Magenta Therapeutics where he was project lead for MGTA-145, a novel biologic designed to mobilize HSCs prior to bone marrow transplant. He previously served as Vice President of Portfolio Strategy at Mersana Therapeutics with responsibility for project leadership, alliance management, and portfolio strategy. Veit also served as Global Project Leader for Takeda Pharmaceuticals International (formerly Millennium Pharmaceuticals) where he was directly responsible for the company’s global asset strategy for new pipeline projects, overseeing programs in oncology from late-stage discovery through preclinical development and approval. Notably, Veit directed the global development of Entyvio® through Phase 2 and 3 clinical development, MAA/BLA review, global approvals, and launch. Veit began his career at Boehringer Ingelheim where he held positions of increasing seniority, becoming the Head of the Department of Chemistry, Manufacturing, and Control for its Japanese subsidiary.
Veit is a board-certified pharmacist in Germany and he obtained a PhD from Heidelberg University with a focus in formulation development.